{'fraction_non_alphanumeric': 0.022565320665083134, 'fraction_numerical': 0.011876484560570071, 'mean_word_length': 6.1440677966101696, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Contemporary use of antiplatelet therapies in percutaneous coronary interventions

Introduction Interventional cardiology is a rapidly developing field with continually expanding revascularization indications in cardiovascular diseases. Since the first coronary angioplasty performed by Gruntzig et al. in 1977 [1], the number of procedures performed per year has progressively increased. It is estimated that over a million percutaneous coronary interventions (PCI) were performed in 1999 in the USA as reported by the American Heart Association [2]. The major contributors to the success and popularity of PCI include stent utilization with reduction of restenosis and potent antiplatelet therapies (aspirin, thienopyridines and glycoprotein (GP) IIb/IIIa receptor antagonists) reducing periprocedural and long-term morbidity and mortality.